Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 26;12(12):2095-2098.
doi: 10.21037/tp-23-421. Epub 2023 Dec 19.

Challenges in the treatment of pediatric acute lymphoblastic leukemia: insights from the pediatric real world CAR consortium regarding nonresponse and relapse post tisagenlecleucel

Peter Bader #  1 , Laura M Moser #  1
Affiliations
Editorial

Challenges in the treatment of pediatric acute lymphoblastic leukemia: insights from the pediatric real world CAR consortium regarding nonresponse and relapse post tisagenlecleucel

Peter Bader et al. Transl Pediatr. .
No abstract available

Keywords: CD19-CAR-T-cell therapy; immunotherapy; pediatric B-ALL.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-421/coif). P.B. reports that he has received a research grant for CAR-T cell characterization and payment for lectures about the CAR-T cell topic from Novartis, as well as royalties and consulting fees from Medac, payment for lectures from Medac, Neovii and Amgen, and support for attending meetings from Neovii and Medac, which have not relevant for this article. The other author has no conflicts of interest to declare.

Comment on

References

    1. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18. 10.1056/NEJMoa1215134 - DOI - PMC - PubMed
    1. Foundation EW. Emily Whitehead - 11 years cancer free. 2023. Available online: https://emilywhiteheadfoundation.org/news/celebrating-11-years-cancer-free/
    1. Schultz LM, Eaton A, Baggott C, et al. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 2023;41:354-63. 10.1200/JCO.22.01076 - DOI - PMC - PubMed
    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018;378:439-48. 10.1056/NEJMoa1709866 - DOI - PMC - PubMed
    1. Laetsch TW, Maude SL, Rives S, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol 2023;41:1664-9. 10.1200/JCO.22.00642 - DOI - PMC - PubMed